Stocks: (SNE)(CHL)(CHU)(CN)(PCW)(HBC) Asian markets were mixed as the Nikkei moved up sharply. The Nikkei rose .9% to 17,238. Sony rose on an upgrade from Goldman Sachs. The Hang Seng fell .7% to 19,890. Cathay…
Apple is about to announce a deal that will launch its much anticipated iPhone and it will be available to subscribers to the Cingular cell service owned by AT&T. Apple hopes that its new…
For those of us who have spent years on the floor of the Consumer Electronics floor, one thing stands out. Ninety percent of the thousands of items on display never make it to the…
According to The Wall Street Journal, GE (GE) is taking bids for its plastics unit which it hopes to sell for $10 billion. According to Reuters, Sprint (S) offered a mediocre outlook for 2007…
By William Trent, CFA of Stock Market Beat UMC breaks ground on $5 billion 300mm fab – Semiconductor Fabtech UMC has started construction of its third 300mm fab at an estimated cost of $5…
By William Trent, CFA of Stock Market Beat Last month, astute observers (defined as those with a pulse) could notice that there were an awful lot of companies in the wireless food chain announcing…
From Chad Brand of Peridot Capitalist In a perfect world, stock brokers would actually earn their money. If they recommend individual stocks to their clients, those stocks would do better than the ones chimpanzees…
From Ticker Sense The over-riding theme among the major business headlines over the weekend was that the stronger than expected employment report caused investors to sell equities as the Fed is now expected to…
By Yaser Anwar, CSC of Equity Investment Ideas JPM has posted strong revenues in 2006, driven by solid investment banking fees and excellent trading performance. Management’s outlook for 2007 investment banking is very positive…
From AAO Weblog Last June, the FASB released an interpretation of Statement No. 109, which deals with income tax accounting. It was called Interpretation No. 48 (catchy, eh?), “Accounting for Uncertainty in Income Taxes”…
From AAO Weblog Maybe the Paulson Committee should be mindful of that old chestnut of moms everywhere. According to this story in the New York Post, there’s good news and bad news for the…
From BioHealth Investor Biotechnology POLYMEDIX INC +60.00% SEATTLE GENETICS I +24.01% CYCLACEL PHARMACEUTI +20.93% INNCARDIO INC +19.05% PIPEX PHARMACEUTICAL +12.78% Diagnostic Substances IMMUNOMEDICS INC +16.85% ICAGEN, INC. +13.57% GENE LOGIC INC +4.24% CYTOGEN CORP…
From BioHealth Investor by H.S. AyoubBioHealth Investor.com The major biotech indices were mixed on Monday. The AMEX Biotechnology Index (^BTK) gained more than 3 points, ending trading at $761.54, while the Nasdaq Biotech Index…
On Monday night’s MAD MONEY show on CNBC Jim Cramer said there is noreason to wait for the J.P.Morgan Biotech conference, because healready has the stocks to play. This makes for many short-term andlong-term…
Cramer also wanted to review some IPO’s of 2006 that didn’t work out well at all to see if they were overlooked. His #1 overlooked IPO is Optium (OPTM). Because of all the telecom…
After years of investors and the press saying that GE (GE) would have to resturcture to get its stock moving North again, perhaps the deaf ears are open. GE is selling is large plastics…
Tonight Cramer said tonight on his MAD MONEY show on CNBC there is no reason to wait for the J.P.Morgan Biotech conference, because he already has the stocks to play. Thermo Fisher (TMO) presents…
Tonight Cramer said tonight on his MAD MONEY show on CNBC there is no reason to wait for the J.P.Morgan Biotech conference, because he already has the stocks to play. This makes for many…
Juniper Networks (JNPR-NASDAQ) is filling more of its vacant management positions. Juniper named Stephen Elop as its Chief Operating Officer. He served as president of worldwide field operations at Adobe Systems (ADBE) after the…
Osiris Therapeutics (OSIR) was notified that its PROCHYMAL received FDA ‘Fast Track’designation, expediting thedevelopment of the stem cell treatment for Crohn’s Disease that fails to respond to standard therapies. This takes it to Phase…